Rintodestrant

**Semantic type:** Pharmacologic Substance

**Definition:** An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.

**Synonyms:** - G1T48 - RINTODESTRANT - SERD G1T48 - Selective Estrogen Receptor Degrader G1T48 - Selective Estrogen Receptor Downregulator G1T48